Syncom Formulations (India) Limited Market Cap ($207.48 Million)
Market Cap & Net Worth: Syncom Formulations (India) Limited (SYNCOMF)
Syncom Formulations (India) Limited market cap. Syncom Formulations (India) Limited (NSE:SYNCOMF) has a market capitalization of $207.48 Million (Rs19.19 Billion) as of October 30, 2026. Listed on the NSE stock exchange, this India-based company holds position #16257 globally and #831 in its home market, demonstrating a -7.52% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Syncom Formulations (India) Limited's stock price Rs20.41 by its total outstanding shares 940000000 (940.00 Million).
Syncom Formulations (India) Limited Market Cap History (2022–2026)
Syncom Formulations (India) Limited market cap history from 2022 to 2026. Data shows growth from $89.97 Million to $207.48 Million (26.38% CAGR). Check SYNCOMF live share price for real-time trading data and today's change.
Syncom Formulations (India) Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Syncom Formulations (India) Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see SYNCOMF operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.03x
Syncom Formulations (India) Limited's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.29x
Syncom Formulations (India) Limited's market cap is 0.29 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $89.97 Million | $2.18 Billion | $197.90 Million | 0.04x | 0.45x |
| 2023 | $152.99 Million | $2.24 Billion | $200.71 Million | 0.07x | 0.76x |
| 2024 | $203.31 Million | $2.63 Billion | $253.14 Million | 0.08x | 0.80x |
| 2025 | $144.96 Million | $4.65 Billion | $494.35 Million | 0.03x | 0.29x |
Competitor Companies of SYNCOMF by Market Capitalization
Companies near Syncom Formulations (India) Limited in the global market cap rankings as of October 30, 2026. See net asset quality index of Syncom Formulations (India) Limited to understand what proportion of total assets are financed by equity.
Key companies related to Syncom Formulations (India) Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Syncom Formulations (India) Limited (2022–2026)
Market capitalization of Syncom Formulations (India) Limited from 2022 to today. Between 2022 and today, Syncom Formulations (India) Limited's market cap moved from $89.97 Million to $ 207.48 Million, with a yearly change of 26.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs207.48 Million | +43.13% |
| 2025 | Rs144.96 Million | -28.70% |
| 2024 | Rs203.31 Million | +32.89% |
| 2023 | Rs152.99 Million | +70.06% |
| 2022 | Rs89.97 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Syncom Formulations (India) Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $207.48 Million USD |
| MoneyControl | $207.48 Million USD |
| MarketWatch | $207.48 Million USD |
| marketcap.company | $207.48 Million USD |
| Reuters | $207.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Syncom Formulations (India) Limited
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India and internationally. It operates through Manufacturing and Dealing in Pharmaceutical Drug and Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, dry syrups and su… Read more